See how the Light Adjustable Lens™ (LAL®) is transforming practices and patient outcomes. Hear firsthand from eye care specialists who have successfully integrated the Light Adjustable Lens into their practice.

The Eye Centers of Racine & Kenosha

Georgia Eye Partners

Center for Sight

Coastal Eye

Juliette Eye Institute

Mosaddegh Eye Institute

Chicago Cornea Consultants

Eye Health Northwest

West Coast Eye Institute

Alliance Vision Institute

Eye Specialists & Surgeons of Northern Virginia

ICON Eyecare

Bishop Eye Center
We’re happy to answer. Fill out the form below to submit your question(s) and someone from the RxSight team will get back to you in a timely manner. Can’t find a topic? Use the form to send us your requested topics that may be featured in a future session.
The Light Adjustable Lens provides optimized vision for patient satisfaction.2
Light Adjustable Lens patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).
Since the Light Adjustable Lens is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.
The Light Adjustable Lens offers LASIK-like accuracy in cataract surgery.2,3
92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).
Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.
The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.
The Light Adjustable Lens corrects as low as 0.50 D of astigmatism, which is the lowest level approved to be treated.